1. Efe C, Ozaslan E, Nasiroglu N, Tunca H, Purnak T, Altiparmak E. The development of autoimmune hepatitis and primary biliary cirrhosis overlap syndrome during the course of connective tissue diseases: report of three cases and review of the literature. Dig Dis Sci. 2010; 55:2417–2421.
Article
2. Toyoda M, Yokomori H, Kaneko F, Yoshida H, Hoshi K, Takeuchi H, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome concomitant with systemic sclerosis, immune thrombocytopenic purpura. Intern Med. 2009; 48:2019–2023.
Article
3. West M, Jasin HE, Medhekar S. The development of connective tissue diseases in patients with autoimmune hepatitis: a case series. Semin Arthritis Rheum. 2006; 35:344–348.
Article
4. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009; 50:291–308.
Article
5. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. ; American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010; 51:2193–2213.
6. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013; 65:2737–2747.
Article
7. Marí-Alfonso B, Simeón-Aznar CP, Guillén-Del Castillo A, Rubio-Rivas M, Trapiella-Martínez L, Todolí-Parra JA, et al. RESCLE Investigators, Systemic Autoimmune Diseases Study Group (GEAS). Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: characteristics and survival of patients from the Spanish RESCLE Registry. Semin Arthritis Rheum. 2018; 47:849–857.
Article
8. Takahashi A, Abe K, Yokokawa J, Iwadate H, Kobayashi H, Watanabe H, et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 2010; 40:1092–1097.
Article
9. Gorlova O, Martin JE, Rueda B, Koeleman BP, Ying J, Teruel M, et al. Spanish Scleroderma Group. Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet. 2011; 7:e1002178.
Article
10. Agarwal SK, Reveille JD. The genetics of scleroderma (systemic sclerosis). Curr Opin Rheumatol. 2010; 22:133–138.
Article
11. Ngu JH, Gearry RB, Frampton CM, Stedman CA. Autoimmune hepatitis: the role of environmental risk factors: a population-based study. Hepatol Int. 2013; 7:869–875.
Article
12. Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al. USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology. 2005; 42:1194–1202.
Article
13. Arnson Y, Amital H, Guiducci S, Matucci-Cerinic M, Valentini G, Barzilai O, et al. The role of infections in the immunopathogensis of systemic sclerosis--evidence from serological studies. Ann N Y Acad Sci. 2009; 1173:627–632.
Article
14. Fenoglio D, Battaglia F, Parodi A, Stringara S, Negrini S, Panico N, et al. Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. Clin Immunol. 2011; 139:249–257.
Article
15. Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang GX, Moritoki Y, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology. 2006; 43:729–737.
Article
16. Longhi MS, Hussain MJ, Kwok WW, Mieli-Vergani G, Ma Y, Vergani D. Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance reconstitution in type-2 autoimmune hepatitis. Hepatology. 2011; 53:536–547.
Article
17. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016; 387:2630–2640.
Article
18. Zhao L, Tang Y, You Z, Wang Q, Liang S, Han X, et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PLoS One. 2011; 6:e18909.
Article